Ocular Therapeutix (OCUL) Equity Average (2014 - 2026)

Ocular Therapeutix has reported Equity Average for 13 years, with the latest figure at $617.9 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 112.62% year-over-year to $617.9 million; the trailing twelve-month figure through Mar 2026 stood at $617.9 million (up 112.62% YoY), and the FY2025 full-year result was $484.8 million, up 138.55% from the prior year.
• Equity Average for Q1 2026 stood at $617.9 million, up from $456.3 million in the prior quarter.
• The five-year high for Equity Average was $617.9 million in Q1 2026, with the low at $5.5 million in Q3 2023.
• Average Equity Average over 5 years is $212.4 million, with a median of $249.6 million recorded in 2024.
• Year-over-year, Equity Average slumped 91.21% in 2023 and soared 6570.16% in 2024.
• Tracing OCUL's Equity Average over 5 years: stood at $40.8 million in 2022, then increased by 21.29% to $49.5 million in 2023, then soared by 574.22% to $333.7 million in 2024, then soared by 36.74% to $456.3 million in 2025, then soared by 35.43% to $617.9 million in 2026.
• The last three Equity Average figures came in at $617.9 million (Q1 2026), $456.3 million (Q4 2025), and $282.1 million (Q3 2025), per Business Quant data.

Peer Comparison